Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONIC trial of nivolumab with or without short induction therapy in metastatic triple-negative breast cancer
NL-OMON47543Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in triple-negative breast cancer (TNBC) (5 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Progression-free survival (PFS1) by RECIST 1.1 and 12-week progression-free proportion. Started Sep 2016; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON47543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47543.